Michael DeRosa

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

Kevin J. Harrington, Robert L. Ferris, George R. Blumenschein et al. · The Lancet Oncology · 2017 · 417 citations · Full text

Oncology, Neoadjuvant Therapy, Checkmate 141 +11

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

David Cella, Viktor Grünwald, Paul Nathan et al. · The Lancet Oncology · 2016 · 217 citations · Full text

Checkmate 025, Urology, Genitourinary Cancer +4

Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

Martin Reck, Michael Schenker, Ki Hyeong Lee et al. · European Journal of Cancer · 2019 · 212 citations · Full text

Neuropathologic findings in cortical resections (including hemispherectomies) performed for the treatment of intractable childhood epilepsy

Michael A. Farrell, Michael DeRosa, John Curran et al. · Acta Neuropathologica · 1992 · 176 citations

Pediatric Neurosurgery, Neuroanatomy, Neuropathologic Findings +11

Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study

Martin Reck, Fiona Taylor, John R. Penrod et al. · Journal of Thoracic Oncology · 2017 · 106 citations

Checkmate 017, Oncology, Health-related Quality +6